Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Kurata

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Expert Review of Endocrinology & Metabolism|July 13, 2022
Dapagliflozin for the treatment of chronic kidney diseaseYu Kurata, Masaomi Nangaku
Kidney International|August 20, 2023
Use of antibiotics as a therapeutic approach to prevent AKI-to-CKD progressionYu Kurata, Masaomi Nangaku
Kidney International|June 30, 2020
The role of hypoxia in the pathogenesis of lupus nephritisYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Pharmacotherapy|October 23, 2021
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Annals of Translational Medicine|February 5, 2020
Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemiaYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|May 27, 2020
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Internal Medicine (Tokyo, Japan)|August 28, 2018
Extraperitoneal Placement of a Peritoneal Dialysis CatheterYasuna Nakamura, Yu Kurata, Yoshifumi Hamasaki, et al.
Kidney360|April 4, 2022
TRPM2 Plays a Minor Role in AKI and Kidney FibrosisYu Kurata, Tetsuhiro Tanaka, Hana Cernecka, et al.
Physiological Reports|September 14, 2023
Dznep, a histone modification inhibitor, inhibits HIF1α binding to TIMP2 gene and suppresses TIMP2 expression under hypoxiaTomotaka Yamazaki, Imari Mimura, Yu Kurata, et al.
Eneurologicalsci|December 21, 2017
High PR3-ANCA positivity in a patient with chronic inflammatory demyelinating polyneuropathyMasanori Kurihara, Yu Kurata, Izumi Sugimoto, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Expert Review of Endocrinology & Metabolism|July 13, 2022
Dapagliflozin for the treatment of chronic kidney diseaseYu Kurata, Masaomi Nangaku
Kidney International|August 20, 2023
Use of antibiotics as a therapeutic approach to prevent AKI-to-CKD progressionYu Kurata, Masaomi Nangaku
Kidney International|June 30, 2020
The role of hypoxia in the pathogenesis of lupus nephritisYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Pharmacotherapy|October 23, 2021
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Annals of Translational Medicine|February 5, 2020
Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemiaYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|May 27, 2020
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Internal Medicine (Tokyo, Japan)|August 28, 2018
Extraperitoneal Placement of a Peritoneal Dialysis CatheterYasuna Nakamura, Yu Kurata, Yoshifumi Hamasaki, et al.
Kidney360|April 4, 2022
TRPM2 Plays a Minor Role in AKI and Kidney FibrosisYu Kurata, Tetsuhiro Tanaka, Hana Cernecka, et al.
Physiological Reports|September 14, 2023
Dznep, a histone modification inhibitor, inhibits HIF1α binding to TIMP2 gene and suppresses TIMP2 expression under hypoxiaTomotaka Yamazaki, Imari Mimura, Yu Kurata, et al.
Eneurologicalsci|December 21, 2017
High PR3-ANCA positivity in a patient with chronic inflammatory demyelinating polyneuropathyMasanori Kurihara, Yu Kurata, Izumi Sugimoto, et al.
Pageof 2